keyword
MENU ▼
Read by QxMD icon Read
search

Estrogen positive breast cancer

keyword
https://www.readbyqxmd.com/read/28935545/integrated-molecular-analysis-of-tamoxifen-resistant-invasive-lobular-breast-cancer-cells-identifies-mapk-and-grm-mglur-signaling-as-therapeutic-vulnerabilities
#1
REVIEW
Hillary Stires, Mary M Heckler, Xiaoyong Fu, Zhao Li, Catherine S Grasso, Michael J Quist, Joseph A Lewis, Uwe Klimach, Alan Zwart, Akanksha Mahajan, Balázs Győrffy, Luciane R Cavalli, Rebecca B Riggins
Invasive lobular breast cancer (ILC) is an understudied malignancy with distinct clinical, pathological, and molecular features that distinguish it from the more common invasive ductal carcinoma (IDC). Mounting evidence suggests that estrogen receptor-alpha positive (ER+) ILC has a poor response to Tamoxifen (TAM), but the mechanistic drivers of this are undefined. In the current work, we comprehensively characterize the SUM44/LCCTam ILC cell model system through integrated analysis of gene expression, copy number, and mutation, with the goal of identifying actionable alterations relevant to clinical ILC that can be co-targeted along with ER to improve treatment outcomes...
September 18, 2017: Molecular and Cellular Endocrinology
https://www.readbyqxmd.com/read/28935174/timp-3-mrna-expression-levels-positively-correlates-with-levels-of-mir-21-in-in-situ-bc-and-negatively-in-pr-positive-invasive-bc
#2
Nina Petrovic, Ahmad Sami, Jelena Martinovic, Marina Zaric, Irina Nakashidze, Silvana Lukic, Snezana Jovanovic-Cupic
BACKGROUND: Breast carcinomas (BC) belong to a heterogeneous group of malignant diseases. Correct categorization of BC based on molecular biomarkers has a very important role in deciding the proper course of therapy for each patient. It has been already shown that the decrease of TIMP metalloproteinase inhibitor 3 (TIMP-3) together with overexpression of microRNA-21 (miR-21) might be involved in the process of BC invasion. This is the first study that examined relationship among miR-21, TIMP-3 mRNA and TIPM-3 protein levels in BC groups formed according to invasiveness...
September 6, 2017: Pathology, Research and Practice
https://www.readbyqxmd.com/read/28933369/epigenetic-mechanisms-of-tamoxifen-resistance-in-luminal-breast-cancer
#3
REVIEW
Hany A Abdel-Hafiz
Breast cancer is one of the most common cancers and the second leading cause of cancer death in the United States. Estrogen receptor (ER)-positive cancer is the most frequent subtype representing more than 70% of breast cancers. These tumors respond to endocrine therapy targeting the ER pathway including selective ER modulators (SERMs), selective ER downregulators (SERDs) and aromatase inhibitors (AIs). However, resistance to endocrine therapy associated with disease progression remains a significant therapeutic challenge...
July 6, 2017: Diseases (Basel)
https://www.readbyqxmd.com/read/28933271/targeting-cell-necroptosis-and-apoptosis-induced-by-shikonin-via-receptor-interacting-protein-kinases-in-estrogen-receptor-positive-breast-cancer-cell-line-mcf-7
#4
Zahra Shahsavari, Fatemeh Karami-Tehrani, Siamak Salami
Recognition of a new therapeutic agent may activate an alternative programmed cell death for the treatment of breast cancer. Here, it has been tried to evaluate the effects of Shikonin, a naphthoquinone derivative of Lithospermum erythrorhizon, on the induction of necroptosis and apoptosis mediated by RIPK1-RIPK3 in the ER+ breast cancer cell line, MCF-7. In the current study, cell death modalities, cell cycle patterns, RIPK1 and RIPK3 expressions, caspase-3 and caspase-8 activities, reactive oxygen species and mitochondrial membrane potential have been evaluated in the Shikonin-treated MCF-7 cells...
September 19, 2017: Anti-cancer Agents in Medicinal Chemistry
https://www.readbyqxmd.com/read/28929436/endogenous-sex-hormone-exposure-and-repetitive-element-dna-methylation-in-healthy-postmenopausal-women
#5
Devon J Boyne, Christine M Friedenreich, John B McIntyre, Frank Z Stanczyk, Kerry S Courneya, Will D King
PURPOSE: Epigenetic mechanisms may help to explain the complex and heterogeneous relation between sex hormones and cancer. Few studies have investigated the effects of sex hormones on epigenetic markers related to cancer risk such as levels of methylation within repetitive DNA elements. Our objective was to describe the association between endogenous sex hormone exposure and levels of LINE-1 and Alu methylation in healthy postmenopausal women. METHODS: We nested a cross-sectional study within the Alberta Physical Activity and Breast Cancer Prevention Trial (2003-2006)...
September 19, 2017: Cancer Causes & Control: CCC
https://www.readbyqxmd.com/read/28929082/endocrine-therapy-of-estrogen-receptor-positive-breast-cancer-cells-early-differential-effects-on-stem-cell-markers
#6
Euphemia Y Leung, Marjan E Askarian-Amiri, Debina Sarkar, Carole Ferraro-Peyret, Wayne R Joseph, Graeme J Finlay, Bruce C Baguley
INTRODUCTION: Endocrine therapy of breast cancer, which either deprives cancer tissue of estrogen or prevents estrogen pathway signaling, is the most common treatment after surgery and radiotherapy. We have previously shown for the estrogen-responsive MCF-7 cell line that exposure to tamoxifen, or deprivation of estrogen, leads initially to inhibition of cell proliferation, followed after several months by the emergence of resistant sub-lines that are phenotypically different from the parental line...
2017: Frontiers in Oncology
https://www.readbyqxmd.com/read/28927692/prognostic-influence-of-tumor-stroma-on-breast-cancer-subtypes
#7
Sandra Cid, Noemi Eiro, Berta Fernández, Rosario Sánchez, Alejandro Andicoechea, Pablo Ignacio Fernández-Muñiz, Luis O González, Francisco J Vizoso
INTRODUCTION: The objective of the present work was to evaluate the impact of the phenotype of both intratumoral mononuclear inflammatory cells (MICs) and cancer-associated fibroblast (CAFs), assessed as to their expression of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) on prognosis in different breast cancer subtypes. MATERIALS AND METHODS: A total of 247 tumors of patients with primary ductal invasive breast cancer were categorized into 1 of 4 major subtypes, using the 3 standard immunohistochemical markers (estrogen receptor [ER], progesterone receptor [PR], and human epidermal growth factor receptor/Neu 2 [HER2] receptor status)...
August 19, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/28924522/estradiol-as-a-targeted-late-line-therapy-in-metastatic-breast-cancer-with-estrogen-receptor-amplification
#8
Karthik Kota, Adam Brufsky, Steffi Oesterreich, Adrian Lee
Estradiol is a major regulator of growth for the subset of breast cancers that express the estrogen receptor (ER, ESR1). Strategies to block ER action, via reduction of estradiol or direct inhibition of ER, have shown major success in the prevention and treatment of breast cancer. However, most ER-positive (ER+) metastatic breast cancers (MBC) eventually become resistant to these interventions. Interestingly, high dose estrogen can induce apoptosis in breast cancer cell lines, and high-dose estrogen has been used for over 50 years as therapy for ER+ breast cancer...
July 6, 2017: Curēus
https://www.readbyqxmd.com/read/28919786/genetic-variants-in-long-noncoding-rna-h19-contribute-to-the-risk-of-breast-cancer-in-a-southeast-china-han-population
#9
Yuxiang Lin, Fangmeng Fu, Yazhen Chen, Wei Qiu, Songping Lin, Peidong Yang, Meng Huang, Chuan Wang
The long noncoding RNA (lncRNA) H19 is a maternally expressed imprinted gene that plays important roles in tumorigenesis, progression, and metastasis. However, the association between polymorphisms on H19 and breast cancer (BC) susceptibility has remained obscure. In this case-control study, we assessed the interaction between two lncRNA H19 single-nucleotide polymorphisms (SNPs) (rs217727 C>T, rs2839698 C>T) and the risk of BC in a Chinese Han population. In total, 1,005 BC cases and 1,020 healthy controls were enrolled in this study...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/28919579/mri-and-prediction-of-pathologic-complete-response-in-the-breast-and-axilla-after-neoadjuvant-chemotherapy-for-breast-cancer-mri-and-pathologic-complete-response
#10
Joseph J Weber, Maxine S Jochelson, Anne Eaton, Emily C Zabor, Andrea V Barrio, Mary L Gemignani, Melissa Pilewskie, Kimberly J Van Zee, Monica Morrow, Mahmoud El-Tamer
BACKGROUND: In the setting where determining extent of residual disease is key for surgical planning after neoadjuvant chemotherapy (NAC), herein we evaluate reliability of MRI in predicting pathologic complete response (pCR) of the breast primary and axillary nodes following NAC. STUDY DESIGN: Patients who had MRI before and after NAC between 06/2014-08/2015 were identified in a prospective database following IRB approval. Post NAC-MRI of the breast and axillary nodes was correlated with residual disease on final pathology...
September 14, 2017: Journal of the American College of Surgeons
https://www.readbyqxmd.com/read/28915724/c1orf64-is-a-novel-androgen-receptor-target-gene-and-coregulator-that-interacts-with-14-3-3-protein-in-breast-cancer
#11
Ali Naderi
This study investigated the network of genes that are co-expressed with androgen receptor (AR) to discover novel AR targets in breast cancer. Bioinformatics analysis of two datasets from breast cancer cell lines resulted in the identification of an AR-gene signature constituted of 98 genes that highly correlated with AR expression. Notably, C1orf64 showed the highest positive correlation with AR across the datasets with a correlation coefficient (CC) of 0.737. In addition, C1orf64 closely correlated with AR expression in primary and metastatic breast tumors and C1orf64 expression was relatively higher in breast tumors with a lower grade and lobular histology...
August 22, 2017: Oncotarget
https://www.readbyqxmd.com/read/28914763/emerging-estrogenic-pollutants-in-the-aquatic-environment-and-breast-cancer
#12
REVIEW
Sylvain Lecomte, Denis Habauzit, Thierry D Charlier, Farzad Pakdel
The number and amount of man-made chemicals present in the aquatic environment has increased considerably over the past 50 years. Among these contaminants, endocrine-disrupting chemicals (EDCs) represent a significant proportion. This family of compounds interferes with normal hormonal processes through multiple molecular pathways. They represent a potential risk for human and wildlife as they are suspected to be involved in the development of diseases including, but not limited to, reprotoxicity, metabolic disorders, and cancers...
September 15, 2017: Genes
https://www.readbyqxmd.com/read/28914398/characteristics-and-prognosis-of-breast-cancer-after-liver-or-kidney-transplantation
#13
I-Ji Jeong, Sung-Gyu Lee, Young Hoon Kim, Beom Seok Ko, Jong Won Lee, Byung Ho Son, Se-Hyun Ahn, Hee Jeong Kim
PURPOSE: Immunoediting is crucial in cancer development and progression. This study compared the characteristics and prognosis of post-transplant breast cancer (PTBC) patients receiving immunosuppressants and general breast cancer patients. METHODS: Data from the Asan Medical Center Breast Cancer (AMCBC), kidney transplantation, and liver transplantation databases recorded during 1989-2013 were retrospectively analyzed. Four controls of AMCBC cohort per one case of PTBC cohort were selected based on tumor size, lymph node metastasis, and age...
September 15, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28912877/fen1-knockdown-improves-trastuzumab-sensitivity-in-human-epidermal-growth-factor-2-positive-breast-cancer-cells
#14
Xue Zeng, Xiaofang Che, Yun-Peng Liu, Xiu-Juan Qu, Lu Xu, Chen-Yang Zhao, Chun-Lei Zheng, Ke-Zuo Hou, Yuee Teng
Trastuzumab has been widely applied as a treatment for human epidermal growth factor 2 (HER2)-overexpressing breast cancer. However, the therapeutic efficacy of trastuzumab is limited. Flap endonuclease 1 (FEN1) is a multifunctional endonuclease that has a crucial role in DNA recombination and repair. Inhibition of FEN1 is associated with the reversal of anticancer drug resistance. However, it is unclear whether FEN1 is involved in trastuzumab resistance. In the present study, it was demonstrated that trastuzumab increases the expression of FEN1, and FEN1 knockdown significantly enhanced the sensitivity of BT474 cells to trastuzumab (P<0...
October 2017: Experimental and Therapeutic Medicine
https://www.readbyqxmd.com/read/28912152/distinct-effects-of-body-mass-index-and-waist-hip-ratio-on-risk-of-breast-cancer-by-joint-estrogen-and-progestogen-receptor-status-results-from-a-case-control-study-in-northern-and-eastern-china-and-implications-for-chemoprevention
#15
Fei Wang, Liyuan Liu, Shude Cui, Fuguo Tian, Zhimin Fan, Cuizhi Geng, Xuchen Cao, Zhenlin Yang, Xiang Wang, Hong Liang, Shu Wang, Hongchuan Jiang, Xuening Duan, Haibo Wang, Guolou Li, Qitang Wang, Jianguo Zhang, Feng Jin, Jinhai Tang, Liang Li, Shiguang Zhu, Wenshu Zuo, Zhongbing Ma, Fei Zhou, Lixiang Yu, Yujuan Xiang, Liang Li, Shuohao Shen, Zhigang Yu
BACKGROUND: Obesity is a consideration in the pharmacologic intervention for estrogen receptor (ER) positive (ER+) breast cancer risk. Body mass index (BMI) and waist/hip ratio (WHR) have demonstrated different effects on breast cancer risk in relation to estrogen receptor (ER) status, but the results have been inconsistent. Furthermore, the situation in Chinese women remains unclear. MATERIALS AND METHODS: We conducted a case-control study including 1,439 breast cancer cases in Northern and Eastern China...
September 14, 2017: Oncologist
https://www.readbyqxmd.com/read/28912144/androgen-and-estrogen-receptor-imaging-in-metastatic-breast-cancer-patients-as-a-surrogate-for-tissue-biopsies
#16
Clasina M Venema, Lemonitsa H Mammatas, Carolina P Schröder, Michel van Kruchten, Giulia Apollonio, Andor W J M Glaudemans, A H H Bongaerts, Otto S Hoekstra, Henk M W Verheul, Epie Boven, Bert van der Vegt, Erik F de Vries, Elisabeth G E de Vries, Ronald Boellaard, Catharina Willemien Menke-van der Houven van Oordt, Geke Ap Hospers
In addition to the well-known estrogen receptor (ER) and the human epidermal growth factor receptor 2 (HER2), the androgen receptor (AR) is also a potential drug target in breast cancer treatment. Whole body imaging can provide information across lesions within a patient. ER expression in tumor lesions can be visualized by (18)F-fluoroestradiol (FES) PET, and AR expression has been visualized in prostate cancer patients with (18)F-fluorodihydrotestosterone (FDHT) PET. Our aim was to assess the concordance between FDHT- and FES-PET and tumor AR- and ER-expression measured immunohistochemically (IHC) in patients with metastatic breast cancer...
September 14, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28910567/g0s2-represses-pi3k-mtor-signaling-and-increases-sensitivity-to-pi3k-mtor-pathway-inhibitors-in-breast-cancer
#17
Christina Y Yim, Emmanuel Bikorimana, Ema Khan, Joshua M Warzecha, Leah Shin, Jennifer Rodriguez, Ethan Dmitrovsky, Sarah J Freemantle, Michael J Spinella
G0/G1 switch gene 2 (G0S2) is a direct retinoic acid target implicated in cancer biology and therapy based on frequent methylation-mediated silencing in diverse solid tumors. We recently reported that low G0S2 expression in breast cancer, particularly estrogen receptor-positive (ER+) breast cancer, correlates with increased rates of recurrence, indicating that G0S2 plays a role in breast cancer progression. However, the function(s) and mechanism(s) of G0S2 tumor suppression remain unclear. In order to determine potential mechanisms of G0S2 anti-oncogenic activity, we performed genome-wide expression analysis that revealed an enrichment of gene signatures related to PI3K/mTOR pathway activation in G0S2 null cells as compared to G0S2 wild-type cells...
September 14, 2017: Cell Cycle
https://www.readbyqxmd.com/read/28904064/structurally-novel-antiestrogens-elicit-differential-responses-from-constitutively-active-mutant-estrogen-receptors-in-breast-cancer-cells-and-tumors
#18
Yuechao Zhao, Mary J Laws, Valeria Sanabria Guillen, Yvonne Ziegler, Jian Min, Abhishek Sharma, Sung Hoon Kim, David Chu, Ben Ho Park, Steffi Oesterreich, Chengjian Mao, David J Shapiro, Kendall W Nettles, John A Katzenellenbogen, Benita S Katzenellenbogen
Many ERα-positive breast cancers develop resistance to endocrine therapy via mutation of estrogen receptors (ER) whose constitutive activation is associated with shorter patient survival. Because there is now a clinical need for new antiestrogens (AE) against these mutant ER, we describe here our development and characterization of three chemically novel AE that effectively suppress proliferation of breast cancer cells and tumors. Our AE are effective against wild type and Y537S and D538G ER, the two most commonly occurring constitutively active ER...
September 13, 2017: Cancer Research
https://www.readbyqxmd.com/read/28903441/loss-of-steroid-hormone-receptors-is-common-in-malignant-pleural-and-peritoneal-effusions-of-breast-cancer-patients-treated-with-endocrine-therapy
#19
Willemijne A M E Schrijver, Karianne Schuurman, Annelot van Rossum, Ton Peeters, Natalie Ter Hoeve, Wilbert Zwart, Paul J van Diest, Cathy B Moelans
Discordance in estrogen receptor alpha (ERα), progesterone receptor (PR), androgen receptor (AR) and human epidermal growth factor receptor 2 (HER2) status between primary breast cancers and solid distant metastases ("conversion") has been reported previously. Even though metastatic spread to the peritoneal and pleural cavities occurs frequently and is associated with high mortality, the rate of receptor conversion and the prognostic implications thereof remain elusive. We therefore determined receptor conversion in 91 effusion metastases (78 pleural, 13 peritoneal effusions) of 69 patients by immunohistochemistry (IHC) and in situ hybridization...
August 15, 2017: Oncotarget
https://www.readbyqxmd.com/read/28902360/expression-of-periostin-in-breast-cancer-cells
#20
Katarzyna Ratajczak-Wielgomas, Jedrzej Grzegrzolka, Aleksandra Piotrowska, Rafal Matkowski, Andrzej Wojnar, Janusz Rys, Maciej Ugorski, Piotr Dziegiel
Periostin (POSTN) is a protein involved in multiple processes important for cancer development, both at the stage of cancer initiation and progression, as well as metastasis. The aim of this study was to determine the expression of POSTN in the cells of non-invasive ductal breast carcinoma in situ (DCIS) and invasive ductal carcinoma (IDC) and to correlate it with clinicopathological data. Immunohistochemical studies (IHC) were conducted on 21 cases of fibrocystic breast change (FC), 44 cases of DCIS and 92 cases of IDC...
October 2017: International Journal of Oncology
keyword
keyword
67682
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"